BioSpecifics Technologies Corporation to Present at Two Upcoming Investor Conferences in September
Published: Sep 04, 2012
LYNBROOK, N.Y., Sept. 4, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that Tom Wegman, President of BioSpecifics, will present at the following two upcoming investor conferences in September:
- Rodman & Renshaw 14th Annual Healthcare Conference
Monday, September 10, 2012 at 11:40 am EDT
New York, NY
- ThinkEquity 9th Annual Growth Conference
Thursday, September 13, 2012 at 9:30 am EDT
New York, NY
The live webcasts of these presentations may be accessed under "Calendar of Events" in the Investor Relations section of the BioSpecifics' website at www.biospecifics.com. A replay of the webcasts will also be available on the Company's website following the presentations.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase (XIAFLEX®) for twelve clinical indications. Currently, XIAFLEX is marketed in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is also in clinical development for the treatment of several additional promising indications. Auxilium has reported positive top-line results from two recently completed Phase III clinical trials for Peyronie's disease and is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials. Auxilium has entered into three strategic partnerships for development and commercialization outside the U.S. of injectable collagenase for Dupuytren's contracture and Peyronie's disease. Pfizer Inc. has rights in Europe and Eurasia and injectable collagenase is currently marketed as XIAPEX® for Dupuytren's contracture in select European countries. Asahi Kasei Pharma Corporation has rights in Japan and Actelion Pharmaceuticals Canada Inc. has rights in Canada, Australia, Brazil and Mexico. For more information, please visit www.biospecifics.com.
SOURCE BioSpecifics Technologies Corp.